Insulin resistance in HIV protease inhibitor - Associated diabetes

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 3, 1999, Pages 209-216

  Yarasheski, Kevin E ^a   Tebas, Pablo ^a   Sigmund, Catherine ^a   Dagogo Jack, Samuel ^a   Bohrer, Alan ^a   Turk, John ^a   Halban, Philippe A ^b   Cryer, Philip E ^a   Powderly, William G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

AIDS; Glucose metabolism; Insulin release; Metabolic complications; Pancreatic cells

Indexed keywords

C PEPTIDE; GLUTAMATE DECARBOXYLASE; INDINAVIR; INSULIN; PROINSULIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANTIBODY TITER; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0033166168     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-199907010-00005     Document Type: Article

References (36)

1. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA panel. JAMA 1997;277: 1962-9.
2. Department of Health and Human Services (HHS) and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998;47:4382.
3. HaMmer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
5. Flexner C. HIV-Protease inhibitors. N Engl J Med 1998;338:1281-92.
6. Shader RI, Greenblatt DJ. Protease inhibitors and drug interactions - an alert. J. din Psychopharmacol 1996;16:343-4.
7. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-70.
8. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997;127: 947.
9. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor [Letter]. Ann Intern Med 1997;127: 948.
10. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
11. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167-73.
12. Fajans SS. Definition and classification of diabetes including maturity onset diabetes of the young. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental and clinical text. Philadelphia: Lippincott-Raven, 1996:249-60.
13. Weir GC, Bonner-Weir S. Insulin secretion in non-insulin-dependent diabetes mellitus. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental and clinical text. Philadelphia: Lippincott-Raven, 1996:503-8.
14. O'Rahilly S, Gray H, Humphreys PJ, Krook A, Polonsky KS, White A, et al. Brief Report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med 1995;333:1386-90.
15. Azaryan AV, Krieger TJ, Hook VYH. Purification and characteristics of the candidate prohormone processing proteases PC2 and PC1/3 from bovine adrenal medulla chromaffin granules. J Biol Chem 1995;270:8201-8.
16. Mykkanen L, Haffner SM, Hales CN, Rönneman T, Laakso M. The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes 1997;46:1990-5.
17. Phillips DIW, Clark PM, Hales CN, Osmund C. Understanding oral glucose tolerance:comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 1994; 11:286-92.
18. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte Jr D. Disproportionate elevation of immunoreactive proinsulin in Type-2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987;30:698-702.
19. Haffner SM, Mykkänen L, Valdez RA, et al. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab 1994;79:1806-10.
20. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997;46:1725-32.
21. Weinstein SP, Paquin T, Pritsker A, Haber RS. Glucocorticoid-induced insulin resistance: dexamethasone inhibits the activation of glucose transport in rat skeletal muscle by both insulin-and non-insulin-related stimuli. Diabetes 1995;44:441-5.
22. Delaunay F, Khan A, Cintra A, et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997;100:2094-8.
23. 2 enzyme that contains a repeated structural motif homologous to the integral membrane protein binding domain of ankyrin. J Biol Chem 1997;272:11118-27.
24. Daniels SB, Katzenellenbogen JA. HaloEnol lactones. Studies on the mechanism of inactivation of alpha-chymotrypsin. Biochemistry 1986;25:1436-44.
25. 2. J Biol Chem 1997;272: 16069-72.
26. Ramandham S, Gross RW, Han X, Turk J. Inhibition of arachidonate release by secretagogue-stimulated pancreatic islets suppresses both insulin secretion and the rise in beta cell cytosolic calcium concentration. Biochemistry 1993;32:337-46.
27. 2 activity selective for hydrolysis of arachidonate which is stimulated by ATP and specifically localized to islet beta-cells. Biochemistry 1993;32:327-36.
28. Irminger JC, Meyer K, Halban P. Proinsulin processing in the rat insulinoma cell line INS after overexpression of the endoproteases PC2 or PC3 by recombinant adenovirus. Biochem J 1996;320:11-15.
29. Neerman-Arbez M, Sizonenko SV, Halban PA. Slow cleavage at the proinsulin B-chain/connecting peptide junction associated with low levels of endoprotease PC1/3 in transformed beta cells. J Biol Chem 1993;268:16098-16100.
30. Neerman-Arbez M, Cirulli V, Halban PA. Levels of the conversion endoproteases PCI (PC3) and PC2 distinguish between insulin-producing pancreatic islet beta cells and non-beta cells. Biochem J 1994;300:57-61.
31. Arky R, ed. Crixivan. Physicians' desk reference, 52nd edition. Montvale, NJ: Medical Economics, 1998:1625-32.
32. Kahn SE, McCulloch DK, Schwartz MW, Palmer JP, Porte Jr D. Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus. J Clin Endocrinol Metab 1992;74:192-7.
33. Wang P-W, Abbasi F, Carantoni M, Chen Y-DI, Azhar S, Reaven GM. Insulin resistance does not change the ratio of proinsulin to insulin in normal volunteers. J Clin Endocrinol Metab 1997;82: 3221-4.
34. Gharakhanian S, Salhi Y, Nguyen TH, et al. Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors [abstract 642]. VI Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
35. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from H1V-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.
36. Carr A, Thorisdottir A, Samaras K, Kaufmann GR, Chisholm DJ, Cooper DA. Reversibility of protease inhibitor (PI) lipodystrophy syndrome on stopping PIs or switching to nelfinavir [abstract 668]. VI Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.